• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何在促进本地制药生产的同时保护公共卫生?来自巴西健康产业综合体的经验教训。

How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil.

机构信息

a Center for Business Studies , Institute of Education and Research (Insper) , Sao Paulo , Brazil.

出版信息

Glob Public Health. 2018 Apr;13(4):489-502. doi: 10.1080/17441692.2017.1396354. Epub 2017 Nov 3.

DOI:10.1080/17441692.2017.1396354
PMID:29098942
Abstract

The global health community is increasingly advocating for the local production of pharmaceuticals in developing countries as a way to promote technology transfer, capacity building and improve access to medicines. However, efforts to advance drug manufacturing in these countries revive an old dilemma of fostering technological development versus granting access to social services, such as healthcare. This paper explores the case of Brazil, a country that has developed large-scale health-inspired industrial policies, but is, yet, little understood. Brazil's experience suggests that progressive healthcare bureaucrats can create innovative practices for technology and knowledge transfers. It also demonstrates that highly competitive pharmaceutical firms can collaborate with each other, if a government provides them the right incentives. Reforming regulatory policies is crucial for guaranteeing high-quality products in developing countries, but governments must play a crucial role in supporting local firms to adapt to these regulations. These findings send a strong message to global health policymakers and practitioners on the conditions to create a suitable environment for local production of medical products.

摘要

全球卫生界越来越提倡在发展中国家生产药品,以此促进技术转让、能力建设并改善药品的可及性。然而,在这些国家推进药品制造的努力引发了一个古老的困境,即既要促进技术发展,又要让社会服务(如医疗保健)能够惠及民众。本文探讨了巴西的案例,该国制定了大规模的以卫生为导向的产业政策,但人们对其了解甚少。巴西的经验表明,有进取心的医疗保健官僚可以为技术和知识转让创造创新做法。它还表明,如果政府提供正确的激励措施,竞争激烈的制药公司可以相互合作。改革监管政策对于确保发展中国家的高质量产品至关重要,但政府必须在支持当地公司适应这些法规方面发挥关键作用。这些发现为全球卫生政策制定者和实践者传达了一个强烈的信息,即要为医疗产品的本土化生产创造合适的环境,需要具备哪些条件。

相似文献

1
How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health-industry complex in Brazil.如何在促进本地制药生产的同时保护公共卫生?来自巴西健康产业综合体的经验教训。
Glob Public Health. 2018 Apr;13(4):489-502. doi: 10.1080/17441692.2017.1396354. Epub 2017 Nov 3.
2
Corporate social responsibility to improve access to medicines: the case of Brazil.企业社会责任促进药品可及性:以巴西为例
Global Health. 2017 Feb 21;13(1):10. doi: 10.1186/s12992-017-0235-7.
3
[An analysis of the pharmaceuticals market in Vietnam].[越南药品市场分析]
Sante. 2001 Jul-Sep;11(3):155-60.
4
Medical technology and developing countries: the case of Brazil.医疗技术与发展中国家:以巴西为例。
Int J Health Serv. 1986;16(3):363-73. doi: 10.2190/7H41-XEEB-AQYY-0CN6.
5
Expanding drug access in Brazil: lessons for Latin America and Canada.巴西扩大药品可及性:对拉丁美洲和加拿大的启示
Can J Public Health. 2006 Nov-Dec;97(6):I15-8. doi: 10.1007/BF03405239.
6
Pharmaceutical Services and comprehensiveness 30 years after the advent of Brazil's Unified Health System.巴西统一卫生系统建立30年后的药学服务与全面性
Cien Saude Colet. 2018 Jun;23(6):1937-1949. doi: 10.1590/1413-81232018236.09022018.
7
The societal value of pharmaceuticals. Balancing industrial and healthcare policy.药品的社会价值。平衡产业政策与医疗政策。
Pharmacoeconomics. 1996 Jul;10(1):14-22. doi: 10.2165/00019053-199610010-00003.
8
Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.迈向欧洲药品研究战略(2014-2020 年):欧盟制药工业协会联合会关于“地平线 2020”计划的立场文件。
Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020. Epub 2012 Oct 6.
9
The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil.与巴西国家药品政策及疾病负担相比的药品公共生产
Cad Saude Publica. 2017 Sep 28;33(9):e00179815. doi: 10.1590/0102-311X00179815.
10
On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa.在援助正统观念的边缘:巴西与莫桑比克在非洲生产基本药物的合作。
Global Health. 2014 Sep 25;10:70. doi: 10.1186/s12992-014-0070-z.

引用本文的文献

1
Assessment of Local Pharmaceutical Manufacturing Sector in a Low-income Country: A Descriptive Study.低收入国家本地制药制造业评估:一项描述性研究。
Ther Innov Regul Sci. 2025 Mar;59(2):379-396. doi: 10.1007/s43441-025-00756-4. Epub 2025 Feb 7.
2
Do Amazon turtles exposed to environmental concentrations of the antineoplastic drug cyclophosphamide present mutagenic damages? If so, would such damages be reversible?暴露于环境浓度环磷酰胺的亚马逊龟是否会出现致突变损伤?如果是,这些损伤是否可逆?
Environ Sci Pollut Res Int. 2019 Feb;26(6):6234-6243. doi: 10.1007/s11356-019-04155-9. Epub 2019 Jan 13.
3
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries.
当地私营经销商的药品质量保证:13个低收入和中等收入国家的二次分析
BMJ Glob Health. 2018 Jun 9;3(3):e000771. doi: 10.1136/bmjgh-2018-000771. eCollection 2018.
4
Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.通过印度健康影响基金改善药品可及性:利益相关者分析
Glob Health Action. 2018;11(1):1434935. doi: 10.1080/16549716.2018.1434935.